**Opioid Crisis Response** Key Legal Developments Every Health Lawyer and Compliance Officer Should Know

Presented by: Marguerite Ahmann, Andrew Holm, Katherine Ilten, Chelsey Jonason and Pari McGarraugh

February 19, 2020



#### Agenda

- Introduction
- Prescribing matters
- Pharmacy issues
- EKRA
- Medicare and Medicaid reimbursement
- Privacy and health records
- State and local response
- Civil and criminal enforcement



## **Opioid Crisis in the Headlines**

- "Insys Founder Gets 5 ½ Years in Prison in Opioid Kickback Scheme."
- "The Opioid Epidemic Cost \$2.5 Trillion Over 4 Years."
- "D.C. Opioid Deaths are Surging Again, Reversing Previous Year's Decline."
- "As Tens of Thousands Died, F.D.A. Failed to Police Opioids."
- "The Hidden Drug Epidemic Among Older People."



#### **Statistics**

- From 1999 to 2017, more than 702,000 people in the U.S. died from a drug overdose.
- <u>At least</u> two of three drug overdoses in the U.S. involve an opioid.

CDC.gov



#### **Statistics**

- 1999 to 2015: Opioid-related overdose death rose 401%, non-opioid related overdose deaths rose 150% and unspecified overdose deaths rose 220%.
- Breakdown by type of opioid: prescription opioid pain relievers (41.5%); heroin (25.4%); methadone (20.3%); other and unspecified (14.4%); synthetic other than meth (14.2%); and opium (0.01%).

Office of the Surgeon General



#### **Statistics**

- States with highest death rates due to drug overdoses (2017): WV, OH, PA, D.C. and KY.
- States with statistically significant increase in overdose death rates (2016-2017): AL, AZ, CA, CT, DE, FL, GA, IL, IN, KY, LA, ME, MD, MI, NJ, NY, NC, OH, PA, SC, TN, WV and WI.



## **Background Reading**

- "The Family That Built an Empire of Pain." Patrick Raddan Keefe. *The New Yorker.* October 23, 2017.
- "The True Cause of the Opioid Epidemic." Olga Khazan. *The Atlantic*, January 2, 2020.
- Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic. Barry Meier. May 2018.
- Dopesick: Dealers, Doctors, and the Drug Company that Addicted America. Beth Macy. August 2018.



#### Resources

- <u>hhs.gov/opioids</u>
- hrsa.gov/opioids
- justice.gov/opioidawareness/file/896776/down load
- <u>healthlawyers.org/find-a-</u> <u>resource/HealthLawHub/Pages/Opioids.aspx</u>



#### Resources

- <u>deadiversion.usdoj.gov</u>
- time2actmissouri.com
- <u>fsmb.org</u>
- <u>cdc.gov/drugoverdose/prescribing/guideline.h</u>
  <u>tml</u>



## Prescribing

- State medical boards.
- State PDMPs.
- Prescribing limitations in telehealth.
- Potential red flags in prescribing.



#### **State Professional Boards**

- 50 different approaches, always changing.
  - Guidance and resources.
  - Education.
  - Form pain management contract.
  - Dosage limits.



### State Prescription Drug Monitoring Programs (PDMPs)

- Who must use it?
- What is the use requirement?
- What must be reported?
- Timeframe for reporting?
- Who has access?



## State Prescription Drug Monitoring Programs (PDMPs)

- Limitations.
  - Limits on data sharing.
  - Lack of standardization.
  - Lack of funding.
  - Lack of integration into the EMR.



## **Telemedicine Prescribing**

- Federal Ryan Haight Online Pharmacy Consumer Protection Act of 2008 – designed to combat rogue internet pharmacies selling controlled substances online.
  - Prohibited form-only online prescribing for controlled substances.
  - Permitted prescribing of controlled substances via telemedicine if practitioner has conducted an in-person exam or meets a "practice of telemedicine" exception (limited to hospitals, registrant in the room).
  - Practice of telemedicine exceptions are outdated. Counter to direct-topatient service models (e.g., substance use disorder treatment).
  - No "special registration" rules from the DEA.



## **Telemedicine Prescribing**

- 2018 SUPPORT Act included the "Special Registration for Telemedicine Act of 2018" requiring DEA to promulgate special registration regulations by October 24, 2019.
- November 22, 2019: Justice Department announced plans to issue a proposed rule on special registration requirements.
- Still awaiting issuance...



## **Compliance Tips**

- Know your state board requirements.
- Integrate the PDMP check into practice.
- Be aware of commercial payer policies.
- Work with a clinician to review records.



## **Red Flags in Prescribing**

- Excessive Rx numbers.
- High morphine milligram equivalents.
- Dangerous combinations (opioid, benzodiazepine, muscle relaxer).
- Quantity or strength increases indefinitely.
- Prescriber direction to particular pharmacies.
- Rx to multiple family members at same address.
- No or cursory medical exam.



## **Red Flags in Prescribing**

- Ignoring complaints by family members, other professionals.
- Brief visits.
- No medical history requested or obtained.
- Lack of diagnostic testing.
- Rx history not in patient file.
- Urine drug screens not documented or addressed.



## The Role of Pharmacies

- Lessons learned:
  - Monitor suspicious orders and prescribers.
  - Maintain effective controls against diversion.



## **Red Flags in Pharmacies**

- High proportion of controlled substances dispensed.
- Insured patients pay cash.
- Customers are patients of known overprescribing physicians.
- Dispense overlapping prescriptions.



## Eliminating Kickbacks in Recovery Act of 2018 ("EKRA")

- Section 8122 of the SUPPORT Act.
- All-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories, and clinical treatment facilities.
- Criminal penalties:
  - Fines up to \$200,000, imprisonment of up to 10 years, or both.



## **EKRA – Key Considerations**

- Applies to "health care benefit programs" i.e., both government and commercial payors.
- Applies with respect to the soliciting or receipt of remuneration for *any* referrals to recovery homes, clinical treatment facilities, or clinical laboratories, whether or not related to treating substance use disorders.



#### EKRA – Text

- ...with respect to services covered by <u>a health care</u> <u>benefit program</u>, in or affecting interstate or foreign commerce, knowingly and willfully—
  - (1) solicits or receives any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory; or



#### EKRA – Text, cont.

- (2) pays or offers any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind—
  - (A) to induce a referral of an individual to a recovery home, clinical treatment facility, or laboratory; or
  - (B) in exchange for an individual using the services of that recovery home, clinical treatment facility, or laboratory...



## **EKRA – Exceptions**

- Discounts.
  - Discounts obtained by providers or entities under a health care program, if the discounts are disclosed and reflected in the provider's or entity's costs or charges; also mirrors the federal AKS safe harbor for Medicare coverage gap drug discounts.
- Personal Services and Management Contracts (AKS safe harbor).
- Patient Copayments or Coinsurance.
  - Non-routine, good-faith waivers or discounts.
- Federally Qualified Health Center Remuneration (AKS).
- Payments made as part of an approved alternative payment model.



## **EKRA – Exceptions, cont.**

The prohibition does NOT apply to:

- (2) a payment made by an employer to an employee or independent contractor (who has a bona fide employment or contractual relationship with such employer) for employment, if the employee's payment is not determined by or does not vary by—
  - (A) the number of individuals referred to a particular recovery home, clinical treatment facility, or laboratory;
  - (B) the number of tests or procedures performed; or
  - (C) the amount billed to or received from, in part or in whole, the health care benefit program from the individuals referred to a particular recovery home, clinical treatment facility, or laboratory.



### New Medicare Part B Benefit

- OUD treatment services furnished by an Opioid Treatment program (OTP).
  - New benefit pursuant to SUPPORT Act.
  - Covered services include certain medications, counseling, individual and group therapy and toxicology testing.



## Medicare Enrollment of OTPs

- Opioid Treatment Program (OTP) enrollment:
  - Current, valid accreditation by an accrediting body or other entity approved by SAMHSA.
  - Current, valid certification by SAMHSA.
  - CMS-855B application and fee.
  - Provider Agreement.



## **Bundled Payments to OTPs**

- Payments to OTPs are Bundled.
  - Bundle covers OUD treatment services that are furnished by the OTP to an individual during an "episode of care."
- OTP Site of Service (Telecommunications).
  - Certain OUD services furnished by OTPs may be provided via telehealth.
  - Beneficiaries may receive services from home.




# **Payment for Telehealth Services**

- CMS added 3 new HCPCS G codes covering treatment for OUD in 2020.
  - HCPCS code G2086.
  - HCPCS code G2087.
  - HCPCS code G2088.



#### **Medicaid Expansion\***





© 2020 Fredrikson & Byron, P.A.

## **Other Federal Measures**

- SUPPORT Act.
  - MAT covered from October 2020 through September 2025 unless limited exception applies.
- Treatment at Institutions for Mental Disease (IMDs).
  - SUPPORT Act.
  - Section 1115 waivers.



## **Increasing Access via Telehealth**

- Mandated coverage.
- Payment parity.
- Types of authorized practitioners.
- Location requirements.
- Facility or program certification.
- State practice boards.



### **Privacy and Health Records**

- 42 C.F.R. Part 2.
  - Applies to "Part 2 Programs."
  - Generally requires written consent to disclose information that identifies a person as having a Substance Use Disorder.
  - Changes coming!



## State & Local Response

- Pain clinic regulation.
- Local treatment programs funding.
- Licensure of treatment programs.
- Professional licensure.
- Other state policies.



## **Pain Clinic Regulation**

- Regulation and oversight of facilities responsible for prescribing opioids and other pain medication, including:
  - Prescribing and dispensing restrictions;
  - Ownership restrictions; and
  - Inspection, recordkeeping and reporting requirements.



## **Funding/Programs**

- State and local responses vary.
- Federal funding sources, including SAMHSA State Targeted Response and State Opioid Response Grants.
- Integrated vs. carve out OUD/SUD services.



### **Program Licensure**

- Many states are enhancing or modernizing existing facility/program licensure laws.
- Emphasis on MAT-specific requirements.
- Office-based opioid treatment.



### **Professional Licensure**

- Expanding and inconsistent set of providers engage to provide substance use disorder treatment:
  - Licensed or certified alcohol and drug counselors, marriage and family therapists, professional counselors, psychologists, psychiatrists, nurses, physician assistants, etc.
  - Peer recovery support personnel.



### Professional Licensure, cont.

- Refining, modernizing, clarifying and expanding licensure categories.
  - E.g., revising "chemical dependency" professionals to "substance use disorder" professionals; revising of supervision and practice requirements.
- State and national credentialing bodies.



### **Other State Policies**

- Using data analytics to inform policies:
  - Medicaid claims and prescriber data.
  - Program reporting requirements.
- Mini-EKRA legislation.
- Specialty drug courts.



## **Civil & Criminal Enforcement**

- Themes and trends.
- Federal enforcement initiatives.
- Recent actions.
- What's next.
- Opioid MDL update.



### **Themes and Trends**

- Data-driven enforcement.
- Increased funding.
- Focus up the food chain and up the supply/distribution chain.
- Criminal vs. civil.



# **Opioid Fraud and Abuse Detection Unit**

- Announced in August 2017 by DOJ.
  - See <u>https://www.justice.gov/opa/pr/attorney-general-</u> sessions-announces-opioid-fraud-and-abuse-detection-unit
- Focused on data analytics:
  - Prescribing and dispensing patterns outside the norm.
  - Patient outcomes (overdoses).
  - Demographic analysis.



# **Opioid Fraud and Abuse Detection Unit**

 Additional federal prosecutors focused on "investigating and prosecuting health care fraud related to opioids, including pill mill schemes and pharmacies that unlawfully divert or dispense prescription opioids for illegitimate purposes."



# **Opioid Fraud and Abuse Detection Unit, cont.**

 Geographic focus: M.D. Fla., E.D. Mich., N.D. Ala., E.D. Tenn., D. Nev., E.D. Ky., D. Md., W.D. Pa., S.D. Ohio, E.D. Cal., M.D. N.C., and S.D. W.V., and likely to grow.



# **Prescription Interdiction & Litigation Task Force**

- Announced in February 2018 by DOJ.
  - See <u>https://www.justice.gov/opa/pr/attorney-general-sessions-announces-new-prescription-interdiction-litigation-task-force</u>
- "[A]ggressively deploy and coordinate all available criminal and civil law enforcement tools."



# **Prescription Interdiction & Litigation Task Force**

 Focus on "every level of the distribution system" including manufacturers, pharmacies, pain management clinics, drug testing facilities and individual physicians.



# Prescription Interdiction & Litigation Task Force

- Coordinate with state authorities.
- Encourage data sharing across the federal government.
- Evaluate and recommend regulatory and statutory changes.



### **Practice Fusion Settlement**

#### **Department of Justice**

Office of Public Affairs

FOR IMMEDIATE RELEASE

Monday, January 27, 2020

#### Electronic Health Records Vendor to Pay \$145 Million to Resolve Criminal and Civil Investigations

#### Practice Fusion Inc. Admits to Kickback Scheme Aimed at Increasing Opioid Prescriptions



### **Dr. Thomas Keller**

- Being tried for murder in California after five patients overdosed.
- Jury trial scheduled for June on Medicare fraud charges.



## **Rochester Drug Settlement**

FOR IMMEDIATE RELEASE

Tuesday, April 23, 2019

### Manhattan U.S. Attorney And DEA Announce Charges Against Rochester Drug Co-Operative And Two Executives For Unlawfully Distributing Controlled Substances

First Ever Felony Criminal Charges Against a Distributor and its Executives for Illegal Distribution of Controlled Substances



# Effingham Health System Settlement

FOR IMMEDIATE RELEASE

Wednesday, May 16, 2018

### Southern District Of Georgia Announces Largest Hospital Drug Diversion Civil Penalty Settlement in U.S. History



### What's Next

- More powerful uses of data.
- More funding.
- Increase in DEA administrative enforcement?
- Opioid MDL litigation.



## **Collateral Consequences**

- Addiction issues affect health professionals.
- Be aware of collateral consequences.
  - Medicare billing privileges.
  - Exclusion.
  - Licensing.



# **Opioid Multi-District Litigation Update**

- Bellwether trial is currently scheduled for November.
- Test cases are two Ohio counties against major pharmacy retailers.
- Ongoing scope and discovery disputes.



### **The Presenters**



Marguerite Ahmann 612.492.7495 mahmann@fredlaw.com





Andrew Holm 612.492.7221 aholm@fredlaw.com



o**lm** 21 <u>dlaw.com</u>



Katherine Ilten 612.492.7428 kilten@fredlaw.com



Chelsey Jonason 612.492.7284 cjonason@fredlaw.com



Pari McGarraugh 612.492.7480 pmcgarraugh@fredlaw.com





© 2020 Fredrikson & Byron, P.A.